Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model

While deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owi...

Full description

Bibliographic Details
Main Authors: Tong Sun, Xi Guo, Rui Zhong, Chengwei Wang, Hao Liu, Hao Li, Lu Ma, Junwen Guan, Chao You, Meng Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/full
id doaj-562670902a0a491eb979dd26ea2b02da
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Tong Sun
Tong Sun
Xi Guo
Xi Guo
Rui Zhong
Chengwei Wang
Chengwei Wang
Hao Liu
Hao Liu
Hao Li
Lu Ma
Junwen Guan
Chao You
Chao You
Chao You
Meng Tian
Meng Tian
Meng Tian
spellingShingle Tong Sun
Tong Sun
Xi Guo
Xi Guo
Rui Zhong
Chengwei Wang
Chengwei Wang
Hao Liu
Hao Liu
Hao Li
Lu Ma
Junwen Guan
Chao You
Chao You
Chao You
Meng Tian
Meng Tian
Meng Tian
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
Frontiers in Bioengineering and Biotechnology
deferoxamine
blood components
antioxidation
alginate
conjugates
author_facet Tong Sun
Tong Sun
Xi Guo
Xi Guo
Rui Zhong
Chengwei Wang
Chengwei Wang
Hao Liu
Hao Liu
Hao Li
Lu Ma
Junwen Guan
Chao You
Chao You
Chao You
Meng Tian
Meng Tian
Meng Tian
author_sort Tong Sun
title Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
title_short Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
title_full Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
title_fullStr Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
title_full_unstemmed Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
title_sort interactions of alginate-deferoxamine conjugates with blood components and their antioxidation in the hemoglobin oxidation model
publisher Frontiers Media S.A.
series Frontiers in Bioengineering and Biotechnology
issn 2296-4185
publishDate 2020-02-01
description While deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owing to intravenous injection and application in blood-related conditions, however, the blood interactions and antioxidation of the DFO-conjugates and the mechanisms underlying these outcomes remain to be elucidated. In this regard, incubating with three different molecular-weight (MW) alginate-DFO conjugates (ADs) red blood cells (RBCs), coagulation system, complement and platelet were investigated. To prove the antioxidant activity of ADs, we used hemoglobin oxidation model in vitro. ADs did not cause RBCs hemolysis while reversible aggregation and normal deformability ability were observed. However, the coagulation time, particularly APTT and TT, were significantly prolonged in a dose-dependent manner, and fibrinogen was dramatically decreased, suggesting ADs could dominantly inhibit the intrinsic pathways in the process of coagulation. The dose-dependent anticoagulation might be related with the functional groups along the alginate chains. The complements, C3a and C5a, were activated by ADs in a dose-dependent manner through alternative pathway. For platelet, ADs slightly suppressed the activation and aggregation at low concentration. Based on above results, the cross-talking among coagulation, complement and platelet induced by ADs was proposed. The antioxidation of ADs through iron chelation was proved and the antioxidant activity was shown in a MW-dependent manner.
topic deferoxamine
blood components
antioxidation
alginate
conjugates
url https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/full
work_keys_str_mv AT tongsun interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT tongsun interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT xiguo interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT xiguo interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT ruizhong interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT chengweiwang interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT chengweiwang interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT haoliu interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT haoliu interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT haoli interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT luma interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT junwenguan interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT chaoyou interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
AT mengtian interactionsofalginatedeferoxamineconjugateswithbloodcomponentsandtheirantioxidationinthehemoglobinoxidationmodel
_version_ 1725302904029446144
spelling doaj-562670902a0a491eb979dd26ea2b02da2020-11-25T00:37:01ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-02-01810.3389/fbioe.2020.00053520676Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation ModelTong Sun0Tong Sun1Xi Guo2Xi Guo3Rui Zhong4Chengwei Wang5Chengwei Wang6Hao Liu7Hao Liu8Hao Li9Lu Ma10Junwen Guan11Chao You12Chao You13Chao You14Meng Tian15Meng Tian16Meng Tian17Neurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaWest China Brain Research Centre, West China Hospital, Sichuan University, Chengdu, ChinaNeurosurgery Research Laboratory, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, ChinaWest China Brain Research Centre, West China Hospital, Sichuan University, Chengdu, ChinaWhile deferoxamine (DFO) has long been used as an FDA-approved iron chelator, its proangiogenesis ability attracts increasing number of research interests. To address its drawbacks such as short plasma half-life and toxicity, polymeric conjugated strategy has been proposed and shown superiority. Owing to intravenous injection and application in blood-related conditions, however, the blood interactions and antioxidation of the DFO-conjugates and the mechanisms underlying these outcomes remain to be elucidated. In this regard, incubating with three different molecular-weight (MW) alginate-DFO conjugates (ADs) red blood cells (RBCs), coagulation system, complement and platelet were investigated. To prove the antioxidant activity of ADs, we used hemoglobin oxidation model in vitro. ADs did not cause RBCs hemolysis while reversible aggregation and normal deformability ability were observed. However, the coagulation time, particularly APTT and TT, were significantly prolonged in a dose-dependent manner, and fibrinogen was dramatically decreased, suggesting ADs could dominantly inhibit the intrinsic pathways in the process of coagulation. The dose-dependent anticoagulation might be related with the functional groups along the alginate chains. The complements, C3a and C5a, were activated by ADs in a dose-dependent manner through alternative pathway. For platelet, ADs slightly suppressed the activation and aggregation at low concentration. Based on above results, the cross-talking among coagulation, complement and platelet induced by ADs was proposed. The antioxidation of ADs through iron chelation was proved and the antioxidant activity was shown in a MW-dependent manner.https://www.frontiersin.org/article/10.3389/fbioe.2020.00053/fulldeferoxamineblood componentsantioxidationalginateconjugates